Analyzing Dyne Therapeutics (NASDAQ:DYN) and Acerus Pharmaceuticals (OTCMKTS:ASPCF)

Acerus Pharmaceuticals (OTCMKTS:ASPCF) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership and risk.

Profitability

This table compares Acerus Pharmaceuticals and Dyne Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Acerus Pharmaceuticals	-924.33%	N/A	-74.62%
Dyne Therapeutics	N/A	-57.46%	-51.62%

Valuation and Earnings

This table compares Acerus Pharmaceuticals and Dyne Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acerus Pharmaceuticals	$2.12 million	0.80	-$33.82 million	($3.57)	-0.06
Dyne Therapeutics	N/A	N/A	-$235.94 million	($3.56)	-6.96

Acerus Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

96.7% of Dyne Therapeutics shares are held by institutional investors. 20.8% of Dyne Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current recommendations for Acerus Pharmaceuticals and Dyne Therapeutics, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acerus Pharmaceuticals	0	0	0	0	0.00
Dyne Therapeutics	0	1	10	2	3.08

Dyne Therapeutics has a consensus price target of $49.91, suggesting a potential upside of 101.57%. Given Dyne Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Acerus Pharmaceuticals.

Volatility & Risk

Acerus Pharmaceuticals has a beta of 0.69, indicating that its share price is 31% less volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.16, indicating that its share price is 16% more volatile than the S&P 500.

Summary

Dyne Therapeutics beats Acerus Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

About Acerus Pharmaceuticals

Acerus Pharmaceuticals Corp. is a pharmaceutical company. The firm is focused on the commercialization and development of prescription products that improve patient experience, with a focus in the field of men’s health. It focuses on therapeutics for urology, andrology, and endocrinology. Its products include Estrace and Natesto. The company was founded by Bruce D. Brydon, Rolf K. Reininghaus and Mark L. Thompson on September 9, 2008 and is headquartered in Mississauga, Canada.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.